Objective: To formulate criteria of multidrug resistance (mdr1) gene expression for predicting chemotherapy response and prognosis. Methods: Using reverse transcriptionpolymerase chain reaction (RTPCR) assay, the exp...Objective: To formulate criteria of multidrug resistance (mdr1) gene expression for predicting chemotherapy response and prognosis. Methods: Using reverse transcriptionpolymerase chain reaction (RTPCR) assay, the expression of mdr1 gene in 82 breast cancer samples were detected. Results: The data were treated by statistic analysis system (SAS)singlevariate analysis. It showed that the level of mdr1 gene expression clearly deviated from normal to right distribution (P<0.0001), and thus might be divided by quantiles P50 (mdr1/β 2MG=0.2) and P75 (mdr1/β 2MG=0.6), which were taken as the preliminary criteria for analyzing 56 patients' chemosensitivity to ADM、VDS and VCR in vitro and 32 relapsed metastatic patients' chemotherapy response in vivo, seperately. When mdr1/( 2MG(0.2, the ratios of resistance gradually escalated, but there were about 30%～50% of the cases who showed sensitive to the drugs in vitro and effective to chemotherapy in vivo. When mdr1/β 2MG≥0.6, the most of patients showed drug resistance both in vitro and in vivo. Conclusion: According to the abovementioned results, criteria of evaluating mdr1 gene expression level was formulated: the mdr1/β 2MG<0.2 (P50) was considered as negative expression, the ratio≥02～<0.6 (P75) was weakly positive expression, ≥0.6 was strongly positive expression. This indicated that different levels of mdr1 gene expression may reflect objectively drug resistance in vitro and chemotherapy response in vivo.展开更多
文摘Objective: To formulate criteria of multidrug resistance (mdr1) gene expression for predicting chemotherapy response and prognosis. Methods: Using reverse transcriptionpolymerase chain reaction (RTPCR) assay, the expression of mdr1 gene in 82 breast cancer samples were detected. Results: The data were treated by statistic analysis system (SAS)singlevariate analysis. It showed that the level of mdr1 gene expression clearly deviated from normal to right distribution (P<0.0001), and thus might be divided by quantiles P50 (mdr1/β 2MG=0.2) and P75 (mdr1/β 2MG=0.6), which were taken as the preliminary criteria for analyzing 56 patients' chemosensitivity to ADM、VDS and VCR in vitro and 32 relapsed metastatic patients' chemotherapy response in vivo, seperately. When mdr1/( 2MG(0.2, the ratios of resistance gradually escalated, but there were about 30%～50% of the cases who showed sensitive to the drugs in vitro and effective to chemotherapy in vivo. When mdr1/β 2MG≥0.6, the most of patients showed drug resistance both in vitro and in vivo. Conclusion: According to the abovementioned results, criteria of evaluating mdr1 gene expression level was formulated: the mdr1/β 2MG<0.2 (P50) was considered as negative expression, the ratio≥02～<0.6 (P75) was weakly positive expression, ≥0.6 was strongly positive expression. This indicated that different levels of mdr1 gene expression may reflect objectively drug resistance in vitro and chemotherapy response in vivo.
